Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Clinical characteristics of patients affected by heart failure patients with reduced ejection fraction and undergoing SGLT2i therapy
Anno:
2023
Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the clinical characteristics and therapy of HFrEF patients undergoing SGLT2i therapy. Methods. We evaluated the consecutive…
Up to 12 month trends in clinical and biochemical parameters after SGLT2i therapy in patients affected by heart failure patients with reduced ejection fraction
Anno:
2023
Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effects of SGLT2i on some clinical and biochemical parameters as well as the persistence of…